Terms: = Kidney tumors AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
4 results:
1. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
[TBL] [Abstract] [Full Text] [Related]
2. BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma.
Yu YP; Cai LC; Wang XY; Cheng SY; Zhang DM; Jian WG; Wang TD; Yang JK; Yang KB; Zhang C
Cancer Sci; 2020 May; 111(5):1555-1566. PubMed ID: 32128917
[TBL] [Abstract] [Full Text] [Related]
3. Downregulation of keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
Huang H; Wu Y; Fu W; Wang X; Zhou L; Xu X; Huang F; Wu Y
Int J Mol Med; 2019 May; 43(5):2044-2054. PubMed ID: 30896860
[TBL] [Abstract] [Full Text] [Related]
4. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma.
Ronkainen H; Vaarala MH; Kauppila S; Soini Y; Paavonen TK; Rask J; Hirvikoski P
Oncol Rep; 2009 Jun; 21(6):1519-23. PubMed ID: 19424632
[TBL] [Abstract] [Full Text] [Related]
